Table 2.
Patients’ demographics and biomarker between patients with cardiac health and with any cardiac disease
| All patients | Patients with cardiac health | Patients with cardiac disease | p value | |
|---|---|---|---|---|
| N | 117 | 42 | 75 | N/A |
| Patients’ demographics | ||||
| Age, in years | 52 [46–59] | 47 [42–52] | 54 [48–62] | <0.0001 |
| Male | 55 % (64) | 52 % (22) | 56 % (42) | 0.85 |
| Diabetes | 12 % (14) | 7%(3) | 15 % (11) | 0.37 |
| Hypertension | 42 % (49) | 26 % (11) | 51 % (38) | 0.01 |
| Hyperlipidemia | 44 % (52) | 33 % (14) | 51 % (38) | 0.08 |
| Smoking | 28 % (33) | 21 % (9) | 32 % (24) | 0.29 |
| BMI, in kg/m2 | 28 [25–33] | 27 [24–32] | 29 [26–33] | 0.11 |
| Framingham Risk Score | 0.006 | |||
| Low (<10 %) | 62 % (73) | 81 % (34) | 52 % (39) | |
| Intermediate (10–20 %) | 21 % (24) | 12 % (5) | 25 % (19) | |
| High (>20 %) | 17 % (20) | 7%(3) | 23 % (17) | |
| Biomarkers | ||||
| hsTnT, ng/L | 4.89 [<3.00–7.59] | 3.58 [<3.00–5.67] | 5.63 [3.18–8.71] | 0.002 |
| hsCRP, mg/L | 1.37 [0.63–2.98] | 0.82 [0.38–1.67] | 1.93 [0.83–4.49] | 0.0005 |
Framingham Risk Score was stratified according to the ATP III guidelines. hsCRP denotes highly-sensitive C-reactive protein; hsTnT, highly-sensitive troponin T